Straylight levels could be linked to corneal healing

Article

Straylight values improve over time and can be linked to the progression of corneal healing, according to a paper.

Straylight values improve over time and can be linked to the progression of corneal healing, according to a paper.

The prospective study, led by Dr Yan Wang, Tianjin Eye Hospital & Eye Institute, Ophthalmology and Visual Science Key Laboratory, Tianjin Medical University, Tianjin, China, involved 128 consecutive eyes from 66 patients. Thin-flap LASIK with a femtosecond laser was performed in 61 eyes of 31 patients and think-flap LASIK with mechanical microkeratome was performed in 67 eyes of 35 patients.

All eyes were ablated using the VIXS S4 excimer laser system after flap creation. Straylight values were measured with the C-Quant straylight meter preoperatively, 1 day, 1 week, 1 month, 6 months and 1 year postoperatively.

The mean preoperative straylight values were 0.93 ± 0.11 but the postoperative values were 1.00 ± 0.11, 0.98 ± 0.10, and 0.99 ± 0.12 at 1 day, 1 week, and 1 month, respectively in the femtosecond thin-flap LASIK group. These values decreased and returned to the preoperative levels and 6 months and 1 year postoperatively.

The postoperative-preoperative increases in straylight were more reduced in the femtosecond laser group compared to the mechanical microkeratome group at 0.05 ± 0.13 vs 0.10 ± 0.13 at 1 month postoperatively. There was a significant negative correlation between preoperative straylight values and postoperative-preoperative increases.

Straylight levels return to preoperative levels and the results indicate this could be related to the progression of corneal healing.

Please visit the Journal of Refractive Surgery to read the abstract.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.